Internship

Undergraduate Molecular Assay Development Internship

Posted on 11/1/2024

Bristol-Myers Squibb

Bristol-Myers Squibb

10,001+ employees

Develops and delivers biopharmaceutical medicines

Biotechnology
Healthcare

Princeton, NJ, USA

Onsite presence is likely required for this internship.

Category
Genomics
Biology Lab & Research
Biology & Biotech
Requirements
  • Undergraduate with 1-2 years of relevant lab experience in molecular biology, biochemistry or cell biology.
  • Strong understanding of genetics, genomics and molecular biology theory and experimental practices.
  • Excellent communication skills, both written and verbal are required.
  • Proactive at keeping current with literature and reading deeply about field of application.
  • Ability to think outside the box and innovate.
Responsibilities
  • Design, develop, and execute validation of genomics and genetics biomarker assays for clinical trial assays at vendors.
  • Contribute to establishment of lab workflows for genetics and genomics biomarkers analysis.
  • Contribute to cross-functional efforts with other technology teams (eg. FLOW, IHC).
  • Develop strategy and evaluate the utility of novel genomics technologies for translational and clinical applications.

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and heart conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs, offering affordable alternatives that meet the same quality standards as their branded counterparts. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, enhancing access to healthcare. The company's goal is to improve patient outcomes while maintaining a commitment to sustainability and corporate responsibility.

Company Stage

IPO

Total Funding

$33.7B

Headquarters

New York City, New York

Founded

1887

Simplify Jobs

Simplify's Take

What believers are saying

  • BMS's collaboration with Prime Medicine enhances its cell and gene-therapy pipeline.
  • The rise of digital health technologies boosts BMS's R&D efficiency.
  • BMS's focus on biosimilars opens new market opportunities globally.

What critics are saying

  • BMS faces a $6.4 billion lawsuit over Celgene drug approval delays.
  • The 340B Drug Pricing Program lawsuit could lead to regulatory challenges.
  • High financial stakes in the Prime Medicine agreement pose development risks.

What makes Bristol-Myers Squibb unique

  • BMS focuses on oncology, immunology, and cardiovascular diseases for innovative treatments.
  • The company invests heavily in R&D to develop new drugs and therapies.
  • BMS offers both innovative and generic medicines, increasing healthcare accessibility.

Help us improve and share your feedback! Did you find this helpful?

INACTIVE